Cingulate CINGW
NASDAQ CINGW
$0.01 +0.00 (+4.29%)
As of: Sep 9, 2026 · 11:16 AM EDT

Cingulate (CINGW) Change in Accured Expenses (2021 - 2025)

Cingulate's (CINGW) quarterly Change in Accured Expenses came in at $1.3 million in Q4 2025, up 30.94% on a YoY basis from $1.0 million in Q4 2024, and up 20.12% quarter-over-quarter from $1.1 million in Q3 2025.

Analysis

Cingulate (CINGW) Change in Accured Expenses (2021 - 2025) Analysis & Trends

Cingulate (CINGW) has reported Change in Accured Expenses for 5 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 30.94% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 132.33% YoY), and the FY2025 full-year result was $1.5 million, up 132.33% from the prior year.
  • Change in Accured Expenses grew to $1.3 million in Q4 2025 per CINGW's latest filing, from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.7 million in Q4 2023 and bottomed at -$5.0 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $79356.4 across 5 years, with a median of $457992.5 in 2022.
  • The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 519.28% in 2023, then slumped 1292.24% in 2024.
  • Over 5 years, Change in Accured Expenses stood at -$3.4 million in 2021, then soared by 117.44% to $593543.0 in 2022, then soared by 519.28% to $3.7 million in 2023, then slumped by 72.75% to $1.0 million in 2024, then jumped by 30.94% to $1.3 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered $1.3 million, $1.1 million, and -$82352.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Johnson & Johnson 646.10 Bn 625.34 Bn 17.26 Bn 2.32 Bn
2 AbbVie 441.68 Bn 435.11 Bn 12.70 Bn 1.20 Bn
3 Merck 366.62 Bn 359.48 Bn 12.21 Bn -
4 Novartis Ag 266.55 Bn 258.86 Bn 11.24 Bn -
5 Pfizer 159.14 Bn 147.45 Bn 10.94 Bn -
6 Sanofi 52.40 Bn 45.02 Bn 10.79 Bn -
7 Revolution Medicines 44.07 Bn 44.07 Bn - 55.78 Mn
8 Incyte 25.59 Bn 21.05 Bn 1.57 Bn -204.33 Mn
9 United Therapeutics 21.54 Bn 18.88 Bn 683.80 Mn -4.00 Mn
10 Cingulate 100,214.03 100,214.03 - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.31 Mn
Sep 30, 2025 1.09 Mn
Jun 30, 2025 -82,352.00
Mar 31, 2025 -852,914.00
Dec 31, 2024 1.00 Mn
Sep 30, 2024 -404,330.00
Jun 30, 2024 -142,889.00
Mar 31, 2024 -5.00 Mn
Dec 31, 2023 3.68 Mn
Sep 30, 2023 544,458.00
Jun 30, 2023 1.33 Mn
Mar 31, 2023 -358,777.00
Dec 31, 2022 593,543.00
Sep 30, 2022 469,611.00
Jun 30, 2022 -718,523.00
Mar 31, 2022 446,374.00
Dec 31, 2021 -3.40 Mn
Sep 30, 2021 1.54 Mn
Jun 30, 2021 799,362.00
Mar 31, 2021 -257,690.00